These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Interventions for Old World cutaneous leishmaniasis. Heras-Mosteiro J; Monge-Maillo B; Pinart M; Lopez Pereira P; Reveiz L; Garcia-Carrasco E; Campuzano Cuadrado P; Royuela A; Mendez Roman I; López-Vélez R Cochrane Database Syst Rev; 2017 Nov; 11(11):CD005067. PubMed ID: 29149474 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in treatment of leishmaniasis. Akbari M; Oryan A; Hatam G Immunol Lett; 2021 May; 233():80-86. PubMed ID: 33771555 [TBL] [Abstract][Full Text] [Related]
4. Targets for immunochemotherapy in leishmaniasis. Mukhopadhyay D; Saha P; Chatterjee M Expert Rev Anti Infect Ther; 2012 Mar; 10(3):261-4. PubMed ID: 22397558 [No Abstract] [Full Text] [Related]
5. Leishmaniasis and various immunotherapeutic approaches. Taslimi Y; Zahedifard F; Rafati S Parasitology; 2018 Apr; 145(4):497-507. PubMed ID: 27974063 [TBL] [Abstract][Full Text] [Related]
6. Practical guide for the treatment of leishmaniasis. Davidson RN Drugs; 1998 Dec; 56(6):1009-18. PubMed ID: 9878989 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis. Monge-Maillo B; López-Vélez R Drugs; 2013 Nov; 73(17):1889-920. PubMed ID: 24170665 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of cutaneous leishmaniasis]. Lambert D; Mambre B Ann Dermatol Venereol; 1988; 115(5):641-3. PubMed ID: 3058010 [No Abstract] [Full Text] [Related]
10. New developments in the chemotherapy of leishmaniasis. Chance ML Ann Trop Med Parasitol; 1995 Dec; 89 Suppl 1():37-43. PubMed ID: 8745926 [TBL] [Abstract][Full Text] [Related]
11. An update on pharmacotherapy for leishmaniasis. Sundar S; Chakravarty J Expert Opin Pharmacother; 2015 Feb; 16(2):237-52. PubMed ID: 25346016 [TBL] [Abstract][Full Text] [Related]
12. Three decades of clinical trials on immunotherapy for human leishmaniases: a systematic review and meta-analysis. Mota CA; Oyama J; Souza Terron Monich M; Brustolin AÁ; Perez de Souza JV; Murase LS; Ghiraldi Lopes LD; Silva Santos TD; Vieira Teixeira JJ; Verzignassi Silveira TG Immunotherapy; 2021 Jun; 13(8):693-721. PubMed ID: 33853344 [No Abstract] [Full Text] [Related]
13. Development of new antileishmanial drugs--current knowledge and future prospects. Le Pape P J Enzyme Inhib Med Chem; 2008 Oct; 23(5):708-18. PubMed ID: 18671165 [TBL] [Abstract][Full Text] [Related]
14. Application of nanotechnology in treatment of leishmaniasis: A Review. Akbari M; Oryan A; Hatam G Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection. Khalili G; Dobakhti F; Mahmoudzadeh-Niknam H; Khaze V; Partovi F Iran J Immunol; 2011 Mar; 8(1):45-51. PubMed ID: 21427495 [TBL] [Abstract][Full Text] [Related]
17. Interventions for Old World cutaneous leishmaniasis. González U; Pinart M; Reveiz L; Alvar J Cochrane Database Syst Rev; 2008 Oct; (4):CD005067. PubMed ID: 18843677 [TBL] [Abstract][Full Text] [Related]
18. Paromomycin in the treatment of leishmaniasis. Sundar S; Chakravarty J Expert Opin Investig Drugs; 2008 May; 17(5):787-94. PubMed ID: 18447603 [TBL] [Abstract][Full Text] [Related]
19. Challenges and new discoveries in the treatment of leishmaniasis. Singh S; Sivakumar R J Infect Chemother; 2004 Dec; 10(6):307-15. PubMed ID: 15614453 [TBL] [Abstract][Full Text] [Related]